Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Andrea Iskenderian"'
Autor:
Hoa Q. Nguyen, Andrea Iskenderian, David Ehmann, Paul Jasper, Zhiwei Zhang, Haojing Rong, Devin Welty, Rangaraj Narayanan
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 6, Pp 342-352 (2020)
Quantitative understanding about the dynamics of drug–target interactions in biological systems is essential, especially in rare disease programs with small patient populations. Follistatin, by antagonism of myostatin and activin, which are negativ
Externí odkaz:
https://doaj.org/article/989002c80fa045f481784c21bfd34edd
Autor:
Andrea Iskenderian, Nan Liu, Qingwei Deng, Yan Huang, Chuan Shen, Kathleen Palmieri, Robert Crooker, Dianna Lundberg, Niksa Kastrapeli, Brian Pescatore, Alla Romashko, John Dumas, Robert Comeau, Angela Norton, Jing Pan, Haojing Rong, Katayoun Derakhchan, David E. Ehmann
Publikováno v:
Skeletal Muscle, Vol 8, Iss 1, Pp 1-16 (2018)
Abstract Background Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin a
Externí odkaz:
https://doaj.org/article/67bfaa2651914f7787073ccc6974c8c1
Autor:
Paul Jasper, David Ehmann, Andrea Iskenderian, Devin Welty, Zhiwei Zhang, Hoa Q. Nguyen, Haojing Rong, Rangaraj Narayanan
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 6, Pp 342-352 (2020)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Quantitative understanding about the dynamics of drug-target interactions in biological systems is essential, especially in rare disease programs with small patient populations. Follistatin, by antagonism of myostatin and activin, which are negative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72be8a4a714484e01d65c0117a1ee15d
https://doaj.org/article/989002c80fa045f481784c21bfd34edd
https://doaj.org/article/989002c80fa045f481784c21bfd34edd
Autor:
Kathleen Palmieri, Bohong Zhang, Muthuraman Meiyappan, Sheng Gu, Matthew Traylor, Brian Pescatore, Robert Crooker, Angela W. Norton, David E. Ehmann, Clark Pan, Dianna Lundberg, George Baviello, Chuan Shen, Qingwei Deng, Bettina Strack-Logue, Alla Romashko, Tao He, Andrea Iskenderian, Haojing Rong, John Gill
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 366:291-302
Follistatin (FS) is an important regulatory protein, a natural antagonist for transforming growth factor-β family members activin and myostatin. The diverse biologic roles of the activin and myostatin signaling pathways make FS a promising therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b31d0c29b0ec54cf1d6e1bd8246deac9
https://doi.org/10.1124/jpet.118.248195
https://doi.org/10.1124/jpet.118.248195
Autor:
Brian Dwyer, Angela W. Norton, Andrea Iskenderian, Dianna Lundberg, Jin Xu, Brian Pescatore, Michael F. Concino, Bohong Zhang, Bettina Strack-Logue, Muthuraman Meiyappan
Publikováno v:
Protein Expression and Purification. 170:105589
The cation-independent mannose-6-phosphate receptor (CI-M6PR, aka insulin-like growth factor II receptor or IGFIIR) is a membrane protein that plays a central role in the trafficking of lysosomal acid hydrolases into lysosomes via mannose-6-phosphate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5470470cc508056bbe5715f2870acf93
https://doi.org/10.1016/j.pep.2020.105589
https://doi.org/10.1016/j.pep.2020.105589
Autor:
Jing Pan, Alla Romashko, David E. Ehmann, Katayoun Derakhchan, Angela W. Norton, Andrea Iskenderian, Qingwei Deng, Robert Comeau, Robert Crooker, Nan Liu, John Dumas, Chuan Shen, Niksa Kastrapeli, Dianna Lundberg, Brian Pescatore, Kathleen Palmieri, Haojing Rong, Yan Huang
Publikováno v:
Skeletal Muscle
Skeletal Muscle, Vol 8, Iss 1, Pp 1-16 (2018)
Skeletal Muscle, Vol 8, Iss 1, Pp 1-16 (2018)
Background Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin antagonism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae2104cea901b16f8803bff66aa10bb0
https://pubmed.ncbi.nlm.nih.gov/30368252
https://pubmed.ncbi.nlm.nih.gov/30368252
Autor:
Angela W. Norton, Pranavkumar Shivakumar, Andrea Iskenderian, Kevin Holmes, Sridevi Gutta, Reena Mourya, Nazanin Navabi, Rizwana Islam, Joseph Sypek, Haojing Rong
Publikováno v:
Gastroenterology. 156:S-1507
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2501d3742445fdf77601b5c9291e0309
https://doi.org/10.1016/s0016-5085(19)40848-2
https://doi.org/10.1016/s0016-5085(19)40848-2
Autor:
Lynette C. Cook, Michael A. Jones, Angela W. Norton, Paolo Martini, Sarah M. Peterson, Michael W. Heartlein, Michael F. Concino, Andrea Iskenderian, Alla Romashko, Kristen Tobin, Alicia Gómez-Yafal, Lucy Liaw
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 427 (2010)
BMC Cancer, Vol 10, Iss 1, p 427 (2010)
Background Extracellular human sulfatases modulate growth factor signaling by alteration of the heparin/heparan sulfate proteoglycan (HSPG) 6-O-sulfation state. HSPGs bind to numerous growth factor ligands including fibroblast growth factors (FGF), e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e7c34c7e30eb2f83ef223a9a21f65e6
https://doi.org/10.1186/1471-2407-10-427
https://doi.org/10.1186/1471-2407-10-427